

Contributing Authors vii

Preface xi

Acknowledgments xii

- 1. Clinical Strategies for Cancer Treatment:
The Role of Drugs** 1
Dwight C. Kaufman and Bruce A. Chabner
- 2. Preclinical Aspects of Cancer Drug Discovery
and Development** 17
*Jill I. Johnson, Anne Monks, Melinda G. Hollingshead,
and Edward A. Sausville*
- 3. Pharmacokinetics and Clinical Monitoring** 37
Jerry M. Collins
- 4. Infertility after Cancer Chemotherapy** 50
Richard L. Schilsky
- 5. Carcinogenesis: A Late Complication
of Cancer Chemotherapy** 67
Charles Erlichman and Malcolm Moore
- 6. Steroid Hormone Therapies for Cancer** 85
Matthew J. Ellis and Sandra M. Swain
- 7. Antifolates** 139
Richard A. Messmann and Carmen J. Allegra
- 8. 5-Fluoropyrimidines** 185
Jean L. Grem
- 9. Cytidine Analogs** 265
*Rocio Garcia-Carbonero, David P. Ryan,
and Bruce A. Chabner*
- 10. Purine Antimetabolites** 295
Kenneth R. Hande
- 11. Hydroxyurea** 315
Luis Paz-Ares and Ross C. Donehower
- 12. Antimicrotubule Agents** 329
Eric K. Rowinsky and Ross C. Donehower
- 13. Alkylating Agents** 373
*Kenneth D. Tew, O. Michael Colvin,
and Bruce A. Chabner*

CONTENTS

- 14. Nonclassic Alkylating Agents 415**
*Henry S. Friedman, Steven D. Averbuch,
and Joanne Kurtzberg*
- 15. Cisplatin and Analogs 447**
Eddie Reed
- 16. Bleomycin 466**
John S. Lazo and Bruce A. Chabner
- 17. Antitumor Antibiotics 482**
*Jaap Verweij, Alex Sparreboom,
and Kees Nooter*
- 18. Anthracyclines and Anthracenediones 500**
James H. Doroshow
- 19. Topoisomerase II Inhibitors:
Epipodophyllotoxins, Acridines, Ellipticines,
and Bisdioxopiperazines 538**
*Yves G. Pommier, François Goldwasser,
and Dirk Strumberg*
- 20. Topoisomerase I Targeting Agents:
The Camptothecins 579**
Chris H. Takimoto and Susan G. Arbuck
- 21. Enzyme Therapy: L-Asparaginase 647**
Bruce A. Chabner and Stephen E. Sallan
- 22. Pharmacologic Considerations in
Chemotherapy for Brain Tumors 657**
*Tracy T. Batchelor, Michel P. Gattineau,
and Jeffrey G. Supko*
- 23. Retinoids and Other Differentiating
Agents 678**
Joseph A. Fontana and Arun K. Rishi
- 24. Bisphosphonates 700**
Matthew R. Smith
- 25. Radiation Modifiers 707**
C. Norman Coleman and James B. Mitchell
- 26. Pharmacology of Interferons:
Induced Proteins, Cell Activation,
and Antitumor Activity 752**
*Deborah J. Vestal, Taolin Yi,
and Ernest C. Borden*

- 27. Clinical Pharmacokinetics of Interleukin 1, Interleukin 2, Interleukin 4, Tumor Necrosis Factor, Interleukin 12, and Macrophage Colony-Stimulating Factor 779**
Ronald M. Bukowski, Charles S. Tannenbaum, and James H. Finke
- 28. Colony-Stimulating Factors 829**
William P. Petros
- 29. Antibody-Based Immunotherapies for Cancer 850**
David A. Scheinberg, George Sgouros, and Richard P. Junghans
- 30. Targeted Therapy 891**
Jeffrey W. Clark
- 31. Physical Barriers to Drug Delivery 911**
Brendan D. Curti
- 32. Adoptive Cellular Therapy 925**
Carl H. June

- 33.** Cancer Vaccines 2001 951
Glenn Dranoff
- 34.** Cytokine and Growth Factor and Receptor
Database: Biologic, Molecular, and
Pathophysiologic Properties of
Ligand-Receptor Interactions 960
Eric Schaffer and Dennis D. Taub
- 35.** Inhibitors of Tumor Angiogenesis 988
Ann L. Mellott and William J. Gradishar
- 36.** Pharmacogenetics 998
Robert B. Diasio
- 37.** Chemokine–Chemokine Receptor
Database 2001: Biologic, Molecular,
and Pathophysiologic Properties of
Chemokine-Receptor Interactions 1012
Harry D. Dawson and Dennis D. Taub

Index 1129